Samuel Dagogo-Jack
#21,901
Most Influential Person Now
American academic
Samuel Dagogo-Jack's AcademicInfluence.com Rankings
Samuel Dagogo-Jackbiology Degrees
Biology
#5657
World Rank
#8192
Historical Rank
Physiology
#362
World Rank
#579
Historical Rank
Samuel Dagogo-Jackphilosophy Degrees
Philosophy
#6597
World Rank
#9655
Historical Rank
Logic
#5427
World Rank
#6827
Historical Rank
Download Badge
Biology Philosophy
Samuel Dagogo-Jack's Degrees
- Doctorate Medicine University of Jos
Why Is Samuel Dagogo-Jack Influential?
(Suggest an Edit or Addition)According to Wikipedia, Samuel E. Dagogo-Jack is a Nigerian-American physician. He is the A.C. Mullins Endowed Professor in Translational Research, Professor of Medicine, and Chief of the Division of Endocrinology, Diabetes, and Metabolism at the University of Tennessee Health Science Center. He is also an Editor of the Journal of Clinical Endocrinology & Metabolism.
Samuel Dagogo-Jack's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) (1083)
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. (2020) (636)
- American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. (2015) (607)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016) (606)
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. (2011) (579)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. (2018) (478)
- Memory improvement following induced hyperinsulinemia in alzheimer's disease (1996) (457)
- Plasma Leptin and Insulin Relationships in Obese and Nonobese Humans (1996) (436)
- Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. (2013) (431)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. (2017) (416)
- Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. (1993) (410)
- AACE comprehensive diabetes management algorithm 2013. (2013) (401)
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes (2020) (385)
- Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection (2011) (372)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. (2019) (326)
- Reversal of Hypoglycemia Unawareness, But Not Defective Glucose Counterregulation, in IDDM (1994) (298)
- American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement (2013) (271)
- Increased plasma leptin concentration in end-stage renal disease. (1997) (260)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. (2016) (246)
- AACE/ACE comprehensive diabetes management algorithm 2015. (2015) (243)
- The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. (2006) (232)
- American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. (2013) (218)
- Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. (1993) (191)
- American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. (2014) (166)
- Thyroid function during pregnancy. (1999) (160)
- Robust leptin secretory responses to dexamethasone in obese subjects. (1997) (148)
- Epidemiology of type 2 diabetes: focus on ethnic minorities. (2005) (141)
- Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. (1998) (132)
- Insulin resistance in HIV protease inhibitor-associated diabetes. (1999) (132)
- Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention Program (2008) (124)
- Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum (2010) (122)
- Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction. (2018) (121)
- Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. (1997) (116)
- Reversible muscle weakness in patients with vitamin D deficiency. (1997) (114)
- Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV) (2018) (111)
- Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone (2017) (111)
- Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study (2017) (108)
- Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications (2016) (105)
- Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management. (2003) (103)
- Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease (2020) (95)
- Diabetes Mellitus in Developing Countries and Underserved Communities (2017) (85)
- Diabetes and cancer--an AACE/ACE consensus statement. (2013) (79)
- American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. (2011) (78)
- Posterior Pituitary (2009) (77)
- Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial (2021) (76)
- Hypoglycemia in Type 1 Diabetes Mellitus (2004) (74)
- Diabetes Care in Nigeria. (2016) (72)
- Augmentation of bone mineral density in hirsute women. (1997) (70)
- Hypoglycemia-Induced Autonomic Failure in IDDM is Specific for Stimulus of Hypoglycemia and Is Not Attributable to Prior Autonomic Activation (1994) (68)
- Approach to the patient with new-onset diabetes after transplant (NODAT). (2011) (67)
- Principles and Practice of Nonpharmacological Interventions to Reduce Cardiometabolic Risk (2010) (65)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. (2015) (61)
- Management of Diabetes Mellitus in Surgical Patients (2002) (61)
- Therapy Insight: metabolic and endocrine disorders in sickle cell disease (2008) (59)
- Hyperleptinemia in Patients with End-Stage Renal Disease Undergoing Continuous Ambulatory Peritoneal Dialysis (1998) (56)
- Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study (2016) (56)
- Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease (2016) (54)
- Hormonal regulation of human leptin in vivo: effects of hydrocortisone and insulin (2000) (53)
- Whole body leptin kinetics and renal metabolism in vivo. (1997) (53)
- Comparison of vildagliptin and thiazolidinedione as add‐on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, type 2 diabetes study (2009) (53)
- Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c (2017) (53)
- Prediabetes as a therapeutic target. (2011) (51)
- Primary prevention of type-2 diabetes in developing countries. (2006) (47)
- Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort (2017) (46)
- Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention (2013) (45)
- Lack of racial disparity in incident prediabetes and glycemic progression among black and white offspring of parents with type 2 diabetes: the pathobiology of prediabetes in a biracial cohort (POP-ABC) study. (2014) (44)
- Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study (2016) (43)
- High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients. (1998) (42)
- Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS) (2019) (42)
- Fasting plasma leptin level is a surrogate measure of insulin sensitivity. (2010) (42)
- Inhibition of cortisol biosynthesis decreases circulating leptin levels in obese humans. (2005) (41)
- American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action. (2014) (41)
- HIV Therapy and Diabetes Risk (2008) (39)
- Disparity implications of Medicare eligibility criteria for medication therapy management services. (2010) (38)
- Preventing diabetes-related morbidity and mortality in the primary care setting. (2002) (36)
- Human leptin regulation and promise in pharmacotherapy. (2001) (35)
- Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study (2019) (34)
- Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS) (2017) (33)
- Combination of recreational soccer and caloric restricted diet reduces markers of protein catabolism and cardiovascular risk in patients with type 2 diabetes (2016) (32)
- Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity (2019) (32)
- Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose. (2009) (32)
- Leptin elimination in hyperleptinaemic peritoneal dialysis patients. (1999) (31)
- The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. (2013) (31)
- Dietary habits and leisure-time physical activity in relation to adiposity, dyslipidemia, and incident dysglycemia in the pathobiology of prediabetes in a biracial cohort study. (2015) (31)
- Multiple drug targets in the management of type 2 diabetes. (2002) (30)
- Hyperleptinaemia of end-stage renal disease is corrected by renal transplantation. (1998) (30)
- Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC): design and methods. (2011) (30)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. (2015) (30)
- DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV) (2018) (29)
- Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing's syndrome. (1993) (29)
- TCF7L2 Polymorphism, Weight Loss and Proinsulin∶Insulin Ratio in the Diabetes Prevention Program (2011) (28)
- Role of ceramides in the pathogenesis of diabetes mellitus and its complications. (2020) (28)
- Durable reversal of hypoglycemia unawareness in type 1 diabetes. (1999) (27)
- Basal and stimulated plasma leptin in diabetic subjects. (1999) (27)
- Whole body leptin kinetics and renal metabolism in vivo. (1997) (26)
- Leptin response to glucocorticoid occurs at physiological doses and is abolished by fasting. (2003) (26)
- Genetic Risk of Progression to Type 2 Diabetes and Response to Intensive Lifestyle or Metformin in Prediabetic Women With and Without a History of Gestational Diabetes Mellitus (2014) (25)
- Cerebral transport and metabolism of 1‐11C‐D‐glucose during stepped hypoglycemia (1995) (25)
- Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC) study: baseline characteristics of enrolled subjects. (2013) (25)
- Amino acid signature predictive of incident prediabetes: A case-control study nested within the longitudinal pathobiology of prediabetes in a biracial cohort (2019) (25)
- Regulation and possible significance of leptin in humans: Leptin in health and disease (1999) (24)
- DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes (2020) (24)
- Isolation of the Human LIM/Homeodomain Gene Islet-1 and Identification of a Simple Sequence Repeat 1 (1994) (24)
- Barriers to achieving optimal glycemic control in a multi-ethnic society: a US focus. (2006) (24)
- Ethnic disparity in hemoglobin A1c levels among normoglycemic offspring of parents with type 2 diabetes mellitus. (2012) (24)
- Recombinant human insulin-like growth factor-I (IGF-I) therapy decreases plasma leptin concentration in patients with chronic renal insufficiency (1998) (24)
- Isolation of the human LIM/homeodomain gene islet-1 and identification of a simple sequence repeat polymorphism [corrected]. (1994) (24)
- URINARY EXCRETION OF HUMAN EPIDERMAL GROWTH FACTOR IN THE VARIOUS STAGES OF DIABETIC NEPHROPATHY (1989) (23)
- Preventing diabetes mellitus in developing countries (2012) (23)
- Homologous radioimmunoassay for epidermal growth factor in human saliva. (1985) (23)
- Predicting, managing and preventing new-onset diabetes after transplantation. (2012) (22)
- Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine (2000) (22)
- Energy adaptation to glucocorticoid-induced hyperleptinemia in human beings. (2005) (22)
- Regression from prediabetes to normal glucose regulation: State of the science (2020) (21)
- Plasma lipid levels predict dysglycemia in a biracial cohort of nondiabetic subjects: Potential mechanisms (2016) (20)
- Reproducibility of fasting plasma leptin concentration in lean and obese humans. (1999) (19)
- Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program (2019) (19)
- Primary prevention of cardiovascular disease in pre-diabetes: the glass is half full and half empty. (2005) (19)
- Preventing diabetes mellitus in developing countries (2012) (19)
- Gradient of Risk and Associations with Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations from VERTIS CV. (2020) (18)
- Metabolic syndrome, prediabetes and the science of primary prevention. (2011) (18)
- Epidermal Growth Factor EGF in human saliva: Effect of age, sex, race, pregnancy and sialagogue (1986) (16)
- Impaired leptin response to glucocorticoid as a chronic complication of diabetes. (2000) (16)
- Philip E. Cryer, MD: Seminal Contributions to the Understanding of Hypoglycemia and Glucose Counterregulation and the Discovery of HAAF (Cryer Syndrome) (2015) (16)
- Recruitment strategies and yields for the Pathobiology of Prediabetes in a Biracial Cohort: a prospective natural history study of incident dysglycemia (2013) (15)
- Ertugliflozin and Slope of Chronic eGFR (2021) (15)
- DCCT Results and Diabetes Care in Developing Countries (1995) (15)
- Metabolomic Prediction of Diabetes and Cardiovascular Risk (2012) (14)
- Awareness of Prediabetes Status and Subsequent Health Behavior, Body Weight, and Blood Glucose Levels (2019) (14)
- Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials (2021) (14)
- Genetic Ancestry Markers and Difference in A1c Between African American and White in the Diabetes Prevention Program (2018) (14)
- DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases (2021) (13)
- Glucoregulatory function among African Americans and European Americans with normal or pre-diabetic hemoglobin A1c levels. (2014) (13)
- Biomarkers of insulin action during single soccer sessions before and after a 12-week training period in type 2 diabetes patients on a caloric-restricted diet (2019) (12)
- Predicting Diabetes: Our Relentless Quest for Genomic Nuggets (2012) (12)
- 2015 Presidential Address: 75 Years of Battling Diabetes−Our Global Challenge (2015) (11)
- Sialoadenectomy increases the concentration of immunoreactive epidermal growth factor in the mouse thyroid gland. (1992) (11)
- Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management. (2017) (11)
- Uremic hyperleptinemia: adaptive or maladaptive? (1998) (11)
- Replication of the Association of BDNF and MC4R Variants With Dietary Intake in the Diabetes Prevention Program (2016) (10)
- Five Ms of adherence (2011) (10)
- Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies (2020) (9)
- Iodine Deficiency Disorders in the Iodine-Replete Environment (2009) (9)
- Demonstration of significant epidermal growth factor activity in murine thyroid tissue. (1986) (9)
- Physiology of Glycemic Recovery and Stabilization After Hyperinsulinemic Euglycemic Clamp in Healthy Subjects. (2018) (9)
- Leptin: Regulation and clinical applications (2015) (9)
- Disparity implications of the Medicare medication therapy management eligibility criteria: a literature review (2013) (9)
- Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. (2013) (9)
- Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. (2015) (8)
- A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program (2019) (8)
- Leukocyte count and cardiometabolic risk among healthy participants with parental type 2 diabetes: the Pathobiology of Prediabetes in a Biracial Cohort study. (2012) (8)
- Severe Hypoglycemia and Incident Heart Failure among Adults With Type 2 Diabetes. (2021) (8)
- Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials (2015) (8)
- Dissociation Between Cardiovascular Risk Markers and Clinical Outcomes in African Americans: Need for Greater Mechanistic Insight (2011) (7)
- Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries (2017) (7)
- Ethnic Disparities in Endothelial Function and Its Cardiometabolic Correlates: The Pathobiology of Prediabetes in A Biracial Cohort Study (2018) (7)
- Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act. (2018) (7)
- Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial (2021) (7)
- Chapter 42 – New Drugs and Diabetes Risk: Antipsychotic and Antiretroviral Agents (2006) (7)
- Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study (2020) (7)
- Role of thiazolidinediones in the management of type 2 diabetes: focus on ethnic minority populations. (2006) (7)
- Epidermal growth factor EGF in human saliva: effect of age, sex, race, pregnancy and sialogogue. (1986) (7)
- Increased Salivary Concentration of Human Epidermal Growth Factor in Patients Undergoing CAPD (1991) (7)
- TCF 7 L 2 Polymorphism , Weight Loss and Proinsulin : Insulin Ratio in the Diabetes Prevention Program (2011) (6)
- Relationships between blood pressure and blood glucose among offspring of parents with type 2 diabetes: Prediction of incident dysglycemia in a biracial cohort. (2017) (6)
- Multi-Year Reproducibility of Hyperinsulinemic Euglycemic Clamp-Derived Insulin Sensitivity in Free-Living Adults: Association with Incident Prediabetes in the POP-ABC Study. (2020) (6)
- Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician’s Guide (2016) (5)
- Dietary iodine affects epidermal growth factor levels in mouse thyroid and submaxillary glands. (1994) (5)
- Dynamic Responses to Leptin Secretagogues in Lean, Obese, and Massively Obese Men and Women (2008) (5)
- Salivary epidermal growth factor concentration in thyrotoxicosis. (1995) (5)
- Testosterone regulates epidermal growth factor levels in the thyroid gland of hypothyroid mice. (1992) (5)
- Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus (2022) (5)
- Recognizing iodine deficiency in iodine-replete environments. (2007) (5)
- Parental history of type 2 diabetes is associated with lower resting energy expenditure in normoglycemic subjects (2018) (5)
- Islet cell encapsulation - Application in diabetes treatment. (2021) (5)
- Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia. (2020) (5)
- Understanding and Identifying Pre-diabetes – Can We Halt the Diabetes Epidemic? (2008) (5)
- Running title: amino acids and prediabetes risk in blacks and whites. (2019) (5)
- Trajectories of Body Weight and Fat Mass in Relation to Incident Prediabetes in a Biracial Cohort of Free-Living Adults (2020) (5)
- Effects of medicare part d on disparity implications of medication therapy management eligibility criteria. (2014) (4)
- Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study (2018) (4)
- Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study (2021) (4)
- Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. (2014) (4)
- AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES. (2017) (4)
- Calorie Restriction and Intermittent Fasting: Impact on Glycemic Control in People With Diabetes (2020) (4)
- Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) Study: design of lifestyle intervention (2020) (3)
- Parental History of Type 2 Diabetes Abrogates Ethnic Disparities in Key Glucoregulatory Indices (2018) (3)
- Outcome of lifestyle intervention in relation to duration of pre-diabetes: the Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) study (2022) (3)
- Comment on: Maruthur et al. Does Genetic Ancestry Explain Higher Values of Glycated Hemoglobin in African Americans? Diabetes 2011;60:2434–2438 (2011) (3)
- The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV (2022) (3)
- Comparisons of changes over time in per capita health expenditures across racial and ethnic groups (2010) (3)
- Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial (2022) (3)
- Sickle Cell Trait, European Ancestry, and Longitudinal Tracking of HbA1c Among African Americans: The Jackson Heart Study (2019) (3)
- Predictive utilities of lipid traits, lipoprotein subfractions and other risk factors for incident diabetes: a machine learning approach in the Diabetes Prevention Program (2021) (3)
- Prevention begets prevention — lessons from the Da Qing Study (2019) (3)
- Predictive value positive of MTM eligibility criteria under MMA and ACA in identifying individuals with medication utilization issues (2018) (3)
- Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV (2022) (3)
- A new understanding of goitrogenesis: role of cytokines in the regulation of normal and aberrant thyroid growth. (1995) (2)
- Association of history of heart failure with hospital outcomes of hyperglycemic crises: Analysis from a University hospital and national cohort. (2019) (2)
- Neuroendocrine Regulation of Food Intake (2005) (2)
- Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups (2019) (2)
- The Implementation Of Medicare Part D And The Health Implications Of Medication Therapy Management Eligibility Criteria (2014) (2)
- Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657–664 (2019) (2)
- Five-Year Glycemic Trajectories Among Healthy African-American and European-American Offspring of Parents With Type 2 Diabetes. (2020) (2)
- Plasma FGF-21 and Sclerostin Levels, Glycemia, Adiposity, and Insulin Sensitivity in Normoglycemic Black and White Adults (2021) (2)
- Risk Factors for Longitudinal Resting Heart Rate and Its Associations With Cardiovascular Outcomes in the DCCT/EDIC Study (2021) (2)
- Basal and Dynamic Leptin Secretion: Association with Cardiometabolic Risk and Body Weight Trajectories in African-Americans and European-Americans (2018) (2)
- A Review of its Therapeutic Use as a Long-Acting Agent for the Management of Type 1 and 2 Diabetes Mellitus (2001) (2)
- 791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV (2021) (2)
- Tumor-grade hyperprolactinemia induced by multiple medications in the setting of renal failure. (1999) (2)
- National Trends and Outcomes in Patients with Uncontrolled Diabetes and Related Complications (2018) (2)
- Diabetes in High-Risk Ethnic Populations (2016) (2)
- Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study (2018) (2)
- Preface [Hot Topic:Inflammatory Markers and Mediators: Emerging Therapeutic Targets in Diabetes, Cardiovascular and Metabolic Disorders (Guest Editor: Samuel Dagogo-Jack, MD)]. (2003) (2)
- Cardiovascular outcomes of antidiabetes medications by race/ethnicity: A systematic review and meta-analysis. (2020) (2)
- Physiological and Hormonal Factors that Influence Leptin Production (2015) (2)
- Age related changes in immunoreactive epidermal growth factor concentrations in murine thyroid and submaxillary glands. (1991) (2)
- The role of antipsychotic agents in the development of diabetes mellitus (2009) (2)
- Association of plasma acylcarnitines with insulin sensitivity, insulin secretion, and prediabetes in a biracial cohort (2021) (2)
- Growth factors and the skeletal System (2011) (2)
- Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV (2021) (1)
- Exploring racial and ethnic disparities in medication adherence among Medicare comprehensive medication review recipients (2021) (1)
- Diabetes Risks from Prescription & Non Prescription Drugs: Mechanisms and Approaches to Risk Reduction (2016) (1)
- Health Implications of the MTM Eligibility Criteria In The Affordable Care Act Across Racial And Ethnic Groups. (2014) (1)
- Insulin-Dependent Diabetes Mellitus (1992) (1)
- Cost-Effectiveness of Medication Therapy Management Program Across Racial and Ethnic Groups Among Medicare Beneficiaries. (2022) (1)
- Glycemic Response to Oral Dexamethasone Predicts Incident Prediabetes in Normoglycemic Subjects With Parental Diabetes (2020) (1)
- Multiyear Reproducibility of Clamp-Derived Insulin Sensitivity in Free-Living Humans—Association with Incident Prediabetes in the POP-ABC Study (2018) (1)
- Author's reply: Pitfalls in the use of HbA1c as a diagnostic test (2010) (1)
- Diagnosis and Management of Prediabetes: A Review. (2023) (1)
- QSource quality initiative. Reversing the diabetes epidemic in Tennessee. (2003) (1)
- Hyperlipidaemia in Diabetes Mellitus (1992) (1)
- Diabetes and cardiovascular disease: An overview (2003) (1)
- Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial (2022) (1)
- 783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV (2021) (1)
- People with diabetes and self-reported severe hypoglycaemia have increased mortality risk over 5 years (2012) (1)
- Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin (2022) (1)
- Safety of Degludec versus Glargine in Type 2 Diabetes. (2017) (1)
- Erratum to: Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials (2015) (1)
- Chapter 18 – Primary Prevention of Type 2 Diabetes Mellitus (2006) (1)
- Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692 (2017) (1)
- Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC): Retention Strategies (2013) (1)
- Erratum: Preventing diabetes mellitus in developing countries (Nature Reviews Endocrinology (2012) 8 (557-562) DOI 10.1038/nrendo.2012.46) (2012) (1)
- Reversing the diabetes epidemic in Tennessee (2003) (1)
- Cardiometabolic Risk Factors and Incident Cardiovascular Disease Events in Women vs Men With Type 1 Diabetes (2022) (1)
- Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial (2022) (1)
- 865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV (2022) (1)
- Serum urate and cardiovascular events in the DCCT/EDIC study (2021) (1)
- Leptin and the Kidney (2015) (1)
- Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. (2023) (1)
- 30-OR: Effects of Vitamin D Supplementation by Race and Weight Status on Serum Vitamin D Measures and Diabetes Risk in the D2d Study (2022) (1)
- Diabetic Ketoacidosis, Hyperosmolar Hyperglycaemic Non-ketotic Coma and Lactic Acidosis (1992) (1)
- Comprar Medications and Diabetes Risk Mechanisms and Approach to Risk Reduction | Samuel Dagogo-Jack | 9780199734313 | Oxford University Press (2011) (1)
- Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence. (2021) (1)
- Editorial: The continuum of dysglycemia: Predicting progression from prediabetes to type 2 diabetes. (2017) (1)
- 1507-P: Baseline Metabolite Profiles of Incident Type 2 Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program (DPP) (2019) (0)
- 299 RECOGNITION OF IODINE DEFICIENCY DISORDERS IN THE IODINE-REPLETE ENVIRONMENT. (2007) (0)
- Central and Peripheral Modulators of Appetite and Satiety (2019) (0)
- Diabetes Identity Cards (1992) (0)
- M1 – Approach to Management of Prediabetic States (including PCOS) in a Multi-Ethnic Population (2012) (0)
- Diabetes and insulin resistance in the neuropsychiatric population (2003) (0)
- WCN23-0356 HYPOGLYCEMIA AND KIDNEY EVENTS IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL (2023) (0)
- Hemoglobin A1c Diagnostic Cutoff Differences Between Black and White Persons (2013) (0)
- Racial and ethnic disparities in the enrolment of medicare medication therapy management programs (2023) (0)
- Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial. (2023) (0)
- 786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV (2021) (0)
- 1441-P: Fidelity of BMI and Waist Circumference as Adiposity Measures in White and Black Adults (2022) (0)
- Complications of Diabetes Mellitus (2019) (0)
- 1560-P: A History of CHF Predicts Adverse Outcomes of Hospitalizations for Hyperglycemic Crises—Data from National and Local Cohorts (2019) (0)
- Annals of internal medicine: Comments and responses (2013) (0)
- Effects of ertugliflozin on kidney outcomes in patients with heart failure at baseline in the VERTIS CV trial (2023) (0)
- Cost of Troglitazone Therapy (1998) (0)
- 481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV (2022) (0)
- Diabetes, antidiabetic drugs, and cancer: Separating background risk from iatrogenesis (2013) (0)
- 164-LB: Association of Ceramide and Sphingolipid Species with Incident Prediabetes among Offspring of Parents with Type 2 Diabetes (2022) (0)
- Bariatric surgery and hypoglycemia (2012) (0)
- Racial and ethnic disparities in meeting mtm eligibility criteria based on star ratings compared to mma (2017) (0)
- Monotherapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone (2017) (0)
- Efficacy and Safety by Baseline A1c with Once Weekly Dulaglutide in AWARD Program (2016) (0)
- Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. (2017) (0)
- 1232-P: Beta-Cell Function and Type 2 Diabetes in Africans and Asian Indians (2022) (0)
- HEART FAILURE OUTCOMES CAPTURED BY ADVERSE EVENT REPORTING IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL (2023) (0)
- Association of urinary albumin-to-creatinine ratio with prediabetes risk in normoglycemic, normoalbuminuric adults with parental type 2 diabetes (2023) (0)
- Genetics of Diabetes (1992) (0)
- 130-OR: Does the Duration of Prediabetes Status Affect Reversibility with Lifestyle Intervention? (2019) (0)
- Primary Prevention of Type 2 Diabetes (2019) (0)
- POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV (2021) (0)
- Prediabetes: A Fundamental text. Pathophysiology, Complications, Management, Reversal (2021) (0)
- Role of the HPA Axis in the Metabolic and Baroreflex Components of Hypoglycemia-Associated Autonomic Failure. (2020) (0)
- Management of Diabetes Mellitus in Sub-Saharan Africa (2019) (0)
- Capacity and Efficiency Testing of New Immunoassay Analyzers (2000) (0)
- 1206-P: Association of Hepatic Steatosis Index (HSI) and Fibrosis (Fib) -4 Score with Prediabetes Risk in the POP-ABC Study: Potential Mechanisms (2022) (0)
- Diabetic Eye Disease (1992) (0)
- 1719-P: Plasma Glucose Response to Oral Dexamethasone Predicts Incident Prediabetes in Normoglycemic Offspring of Parents with Type 2 Diabetes (2019) (0)
- Safety of Degludec versus Glargine in Type 2 Diabetes. (2017) (0)
- Diabetic Foot Syndrome (1992) (0)
- Comparative effectiveness of MTM eligibility criteria under ACA and MMA across racial and ethnic groups in medicare (2018) (0)
- Non-insulin-dependent diabetes mellitus. (1988) (0)
- Racial and ethnic disparities in Medicare Part D medication therapy management services utilization (2023) (0)
- Management of Type 2 Diabetes in Underrepresented Minorities in the U.S. (2005) (0)
- 1203-P: Association of Bone Mineral Density (BMD) with Prediabetes in a Biracial Cohort (2022) (0)
- Pregnancy in Diabetic Patients (1992) (0)
- Subclinical Microvascular Lesions among Normoglycemic and Prediabetic Subjects—The PROP-ABC Study (2018) (0)
- Update on Medical Management of Diabetes (2023) (0)
- EFFICACY OF ERTUGLIFLOZIN ON HEART FAILURE HOSPITALIZATION AND HF DEATH ACROSS THE WATCH-DM RISK SCORE: A SECONDARY ANALYSIS OF THE VERTIS CV TRIAL (2022) (0)
- 796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV (2021) (0)
- Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter] (2022) (0)
- IMPACT OF HEART FAILURE ON OUTCOMES OF SEPSIS RELATED HOSPITALIZATIONS (2018) (0)
- Acute destructive hyperparathyroiditis presenting with severe hypercalcemia: a novel association of COVID-19 infection (2023) (0)
- HYPOGLYCEMIA AND CV OUTCOMES IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL (2023) (0)
- 58 PATIENT-TO-PATIENT TELEPHONE INTERVENTION IN DIABETES. (2006) (0)
- PMU39 Effects of the Medicare PART D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Utilization (2021) (0)
- Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries. (2021) (0)
- Uric Acid and Cardiovascular Disease in Type 1 Diabetes (2018) (0)
- Effect of intra-trial mean 25(OH)D level on diabetes risk, by race and weight: an ancillary analysis in the D2d randomized study cohort. (2023) (0)
- SAT-675 Relapsing Diabetic Ketoacidosis During Stepdown from Intensive Care Unit (2020) (0)
- 15. Patient with New-Onset Diabetes after Transplant (NODAT) (2012) (0)
- Abstract #1039882: Recurrent Diabetic Ketoacidosis in A Community Teaching Hospital (2021) (0)
- 1207-P: Hepatic Steatosis Index and Fibrosis-4 Scores in Relation to Cardiometabolic Risk in Healthy Offspring of Parents with Type 2 Diabetes (2022) (0)
- Sulfonylureas and Ischemic Heart Disease (1998) (0)
- 197-LB: microRNA Expression Profiles and Progression from Normoglycemia to Prediabetes in a Biracial Cohort (2020) (0)
- 2426-PUB: Circulating WBC, RBC, and Hemoglobin Level in Relation to Metabolic Syndrome and Incident Prediabetes in a Biracial Cohort of Normoglycemic Subjects with Parental Type 2 Diabetes (2019) (0)
- Surgery in Diabetic Patients (1992) (0)
- 189-LB: Plasma Sphingolipids in Healthy Black and White Adults With or Without Parental Type 2 Diabetes (2022) (0)
- Impact of an intramural competition on outcome of diabetes care. (2003) (0)
- 785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV (2021) (0)
- Association of bone mineral density with prediabetes risk among African-American and European-American adult offspring of parents with type 2 diabetes (2023) (0)
- Response to the letter to the editor by Chapelot (2006) (0)
- Management of Diabetes Mellitus in Sub-Saharan Africa: Focus on Nigeria (2019) (0)
- Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial (2022) (0)
- 859-P: Effects of Ertugliflozin on Uric Acid and Gout-Related Outcomes: Post Hoc Analyses from VERTIS CV (2022) (0)
- IDF2022-0796 Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV (2023) (0)
- Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria (2014) (0)
- 1210-P: Pooled Analysis of the Safety and Efficacy of Ertugliflozin in the Elderly (2019) (0)
- Genetic Markers Explain Differences in HbA1c Levels between African-American (AA) and Non-Hispanic White (NHW) Participants of the Diabetes Prevention Program (DPP) (2018) (0)
- Review for "Mechanisms Underlying the Metabolic Actions of Testosterone in the Human: a Narrative Review" (2020) (0)
- Management of Cardiovascular Disease Risk in Type 2 Diabetes (2015) (0)
- 1123-P: Racial Differences in Glycemia and A1C in the Vitamin D and Diabetes (D2d) Study (2022) (0)
- Prognosis and Cause of Death in Diabetic Patients (1992) (0)
- Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. (2023) (0)
- Dynamic Leptin Secretion in Obesity and Diabetes (2015) (0)
- Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease (2023) (0)
This paper list is powered by the following services:
Other Resources About Samuel Dagogo-Jack
What Schools Are Affiliated With Samuel Dagogo-Jack?
Samuel Dagogo-Jack is affiliated with the following schools:
